Skip to content
Clinical Trials – home

Obeticholic Acid: A Comprehensive Guide for Patients

1 / 4
trials open to patients / all trials
14+
Countries

In short

Obeticholic acid (OCA) is an emerging drug being studied in clinical trials for various liver and metabolic disorders. This article summarizes key findings from recent trials investigating OCA's effects on conditions like primary biliary cholangitis, nonalcoholic fatty liver disease, and bile acid diarrhea. We'll explore how this farnesoid X receptor agonist may impact liver function, cholesterol metabolism, and other health markers in patients with these challenging conditions.

At a glance

Drug Name
Obeticholic Acid (OCA)
Mechanism
Farnesoid X Receptor (FXR) agonist
Main Conditions Studied
Primary Biliary Cholangitis (PBC), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Bile Acid Diarrhea, Lipodystrophy
Key Findings
- Improved liver enzyme levels in PBC patients - Reduced liver fat content in NAFLD/NASH - Potential improvements in cholesterol metabolism - Possible benefits in bile acid diarrhea and lipodystrophy
Common Dosage in Trials
10-25 mg daily
Notable Side Effects
Pruritus (itching), changes in cholesterol levels
Current Approval Status
Approved for PBC; investigational for other conditions
Ongoing Research Focus
Long-term efficacy and safety, optimal dosing, combination therapies

What is Obeticholic Acid?

Obeticholic Acid (OCA) is a medication that has been developed to treat various liver conditions. It's also known by other names such as INT-747, 6α-Ethyl chenodeoxycholic acid (6-ECDCA), and is marketed under the brand name Ocaliva. OCA is a semi-synthetic bile acid, which means it's a modified version of a natural substance found in our bodies.

How Does It Work?

Obeticholic Acid works by activating a specific protein in our body called the Farnesoid X Receptor (FXR). This protein plays a crucial role in regulating bile acids, fats, and sugar in our body. When OCA activates FXR, it can help improve various aspects of liver function and metabolism.

Specifically, OCA can:

  • Reduce the production of bile acids, which can be harmful in excess
  • Improve the flow of bile from the liver
  • Help regulate fat and sugar metabolism in the liver
  • Potentially reduce inflammation and scarring in the liver

Conditions Treated

Obeticholic Acid is being studied and used for several liver-related conditions:

  1. Primary Biliary Cholangitis (PBC): This is a chronic liver disease where the bile ducts in the liver are slowly destroyed. OCA has been approved for use in PBC patients who don't respond well to the standard treatment.
  2. Non-alcoholic Steatohepatitis (NASH): This is a type of fatty liver disease not caused by alcohol. OCA has shown promise in improving liver health in NASH patients.
  3. Non-alcoholic Fatty Liver Disease (NAFLD): This is a broader category that includes NASH. Studies are ongoing to see if OCA can help patients with NAFLD.
  4. Bile Acid Diarrhea: Some research is looking at whether OCA can help patients who have diarrhea caused by bile acid problems.

Dosage and Administration

Obeticholic Acid is typically taken as a tablet by mouth. The dosage can vary depending on the condition being treated and the individual patient. In most studies, doses ranged from 10 mg to 25 mg per day. However, it's crucial to follow your doctor's instructions regarding dosage and administration.

Potential Benefits

Research has shown that Obeticholic Acid may offer several benefits:

  • Improved liver function tests: OCA has been shown to reduce levels of certain enzymes that indicate liver damage.
  • Reduced liver fat: In patients with fatty liver diseases, OCA may help decrease the amount of fat in the liver.
  • Improved bile flow: For conditions like PBC, OCA can help improve the flow of bile from the liver.
  • Potential reduction in liver scarring: Some studies suggest OCA might help reduce fibrosis (scarring) in the liver.

Side Effects

Like all medications, Obeticholic Acid can cause side effects. Some of the reported side effects include:

  • Itching (pruritus): This is the most common side effect.
  • Changes in cholesterol levels: OCA may affect cholesterol levels, particularly increasing LDL ("bad") cholesterol.
  • Fatigue
  • Abdominal pain or discomfort
  • Constipation

It's important to discuss any side effects with your healthcare provider.

Ongoing Research

Obeticholic Acid is still being studied for various conditions and effects. Some areas of ongoing research include:

  • Effects on gut microbiota (the bacteria in our intestines)
  • Impact on gastric motility (how food moves through the stomach and intestines)
  • Potential use in obesity and gallstone disease
  • Long-term effects and safety in various liver conditions

As research continues, we may learn more about how Obeticholic Acid can be used to treat liver and metabolic diseases.

Questions people often ask

Conditions where Obeticholic Acid is being studied

Each condition opens its own overview and trial list

Trials with Obeticholic Acid

Recruiting trials first

See all 4 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).